Per‐Anders Abrahamsson

Publications100
h-index25
Citations2,663
Highly Influential Citations120
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Lilja
  • 383 Publications, 23,834 Citations
  • F. Schroeder
  • 1,007 Publications, 36,073 Citations
  • M. Roobol
  • 657 Publications, 18,882 Citations
  • J. Hugosson
  • 318 Publications, 12,762 Citations
  • Publications
  • Influence
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.
OBJECTIVES This review aims to provide practising clinicians with the most recent knowledge of the biological nature of prostate cancer (PC) to facilitate investigation of new treatment modalities… Expand
  • 238
  • 20
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate… Expand
  • 287
  • 17
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
CONTEXT The well-known side-effect profile of androgen-deprivation therapy (ADT) has significant quality-of-life (QoL) implications. Intermittent androgen deprivation (IAD) alternates androgen… Expand
  • 178
  • 9
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
PURPOSE We examined whether prostate-specific antigen (PSA) forms and human kallikrein 2 (hK2) measured at age 44 to 50 years predict long-term risk of incident prostate cancer. METHODS From 1974… Expand
  • 194
  • 7
Neuroendocrine differentiation in prostatic carcinoma
Information is presented on prostatic neuroendocrine cells and neuroendocrine differentiation in prostatic carcinoma. The prognostic and therapeutic implications of neuroendocrine differentiation in… Expand
  • 258
  • 6
Early detection of prostate cancer: European Association of Urology recommendation.
BACKGROUND The recommendations and the updated EAU guidelines consider early detection of PCa with the purpose of reducing PCa-related mortality and the development of advanced or metastatic disease.… Expand
  • 134
  • 6
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.
Somatostatin (SST) plays an important regulatory role in the physiological control of various organs including the prostate. Somatostatin receptors (SSTRs) and SST analogs are potential targets for… Expand
  • 62
  • 5
Regional distribution of neuroendocrine cells in the urogenital duct system of the male rat
Neuroendocrine (NE) cells are frequently present in the human prostate and urethra, whereas they are lacking in the other urogenital organs. This study was undertaken as there are only few detailed… Expand
  • 10
  • 5
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
BACKGROUND There is little consensus on a standard approach to analysing bone scan images. The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but… Expand
  • 129
  • 4
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
UNLABELLED Despite intense efforts to develop radiotracers to detect cancers or monitor treatment response, few are widely used as a result of challenges with demonstrating clear clinical use. We… Expand
  • 59
  • 4
  • PDF